Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Subcutaneous Isatuximab Administration By an on-Body Delivery System (OBDS) in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Phase 1b Expansion Study Results

Hang Quach, Gurdeep Parmar, Enrique M. Ocio, H. Miles Prince, Albert Oriol, Nobuhiro Tsukada, Kazutaka Sunami, Pierre Bories, Sumit Madan, Dorothee Semiond, Disa Yu, Sandrine Macé, Florence Suzan, Philippe Moreau

Blood (2022) 140 (Supplement 1): 4412–4414.

https://doi.org/10.1182/blood-2022-166840

Published: 2022

Journal Articles

A Multi-Center, Phase 1b Study to Assess the Safety, Pharmacokinetics and Efficacy of Subcutaneous Isatuximab Plus Pomalidomide and Dexamethasone, in Patients with Relapsed/Refractory Multiple Myeloma

Philippe Moreau, Gurdeep Parmar, Miles Prince, Enrique Ocio, Chatchada Karanes, Sumit Madan, Albert Oriol, Pierre Bories, Michel Delforge, Nashat Gabrail, Dorothee Semiond, Nan Jia, Sandrine Macé, Florence Suzan, Helgi van de Velde, Hang Quach

Blood (2021) 138 (Supplement 1): 2744.

https://doi.org/10.1182/blood-2021-147136

Published: 2021

Journal Articles

Real-World Evidence of the Use of Carfilzomib Among Multiple Myeloma Patients with at Least One Prior Therapy across 10 European Countries and Israel

Evangelos Terpos, MDPhD, Borhane Slama, MD, Renato Zambello, Sorina Nicoleta Badelita, MD, Eirini Katodritou, MD, Jo Caers, MD PhD, Thomas Kühr, MD, Florence Suzan, MD, Abeera Mohammad, MSc, Sally Wetten, MSc, Xavier Leleu, MD

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-134475

Published: 2020

Journal Articles

Real-World Evidence of the Use of Approved Carfilzomib Regimens in Patients Previously Exposed or Refractory to Lenalidomide: Updated Results from a Prospective Observational Study

Xavier Leleu, MD, Borhane Slama, MD, Renato Zambello, Sorina Nicoleta Badelita, MD, Eirini Katodritou, MD, Jo Caers, MD PhD, Thomas Kühr, MD, Florence Suzan, MD, Abeera Mohammad, MSc, Sally Wetten, MSc, Evangelos Terpos, MDPhD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-134476

Published: 2020

Journal Articles

Patient's Preference for Making Informed Treatment Decisions Confidently: Results from a Large Multiple Myeloma Patient Survey across 12 Countries in Europe and Israel

Alessandra Brescianini, MD, Renaud Desgraz, MD, Ananda Plate, MSc, Kathryn E. Morgan, MSc, Ana Vallejo, MSc, Sally Wetten, MSc, Lucy DeCosta, MSc, Florence Suzan, MD

Blood (2020) 136 (Supplement 1): 23.

https://doi.org/10.1182/blood-2020-142532

Published: 2020

Journal Articles

Real-World Evidence of the Use of Carfilzomib and Dexamethasone (Kd) By Lenalidomide-Refractory Status: An Interim Analysis from a Prospective Observational Study

Xavier Leleu, MD PhD, Jo Caers, MD PhD, Barbara Gamberi, MD, Maaike Söhne, MD, Sonja Heibl, MD, Florence Suzan, MD, Abeera Mohammad, Sally Wetten, Evangelos Terpos, MD

Blood (2019) 134 (Supplement_1): 5578.

https://doi.org/10.1182/blood-2019-122938

Published: 2019

Journal Articles

Management of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Proteasome Inhibitor Based Therapy at First Relapse in Routine Clinical Practice in Germany

H. Tilman Steinmetz, Moushmi Singh, Andrea Lebioda, Aurelien Mantonnier, Leah Fink, Achim Rieth, Florence Suzan, Sebastian Gonzalez-McQuire

Blood (2018) 132 (Supplement 1): 1953.

https://doi.org/10.1182/blood-2018-99-110937

Published: 2018

NARROW

Subcutaneous Isatuximab Administration By an on-Body Delivery System (OBDS) in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Phase 1b Expansion Study Results

A Multi-Center, Phase 1b Study to Assess the Safety, Pharmacokinetics and Efficacy of Subcutaneous Isatuximab Plus Pomalidomide and Dexamethasone, in Patients with Relapsed/Refractory Multiple Myeloma

Real-World Evidence of the Use of Carfilzomib Among Multiple Myeloma Patients with at Least One Prior Therapy across 10 European Countries and Israel

Real-World Evidence of the Use of Approved Carfilzomib Regimens in Patients Previously Exposed or Refractory to Lenalidomide: Updated Results from a Prospective Observational Study

Patient's Preference for Making Informed Treatment Decisions Confidently: Results from a Large Multiple Myeloma Patient Survey across 12 Countries in Europe and Israel

Real-World Evidence of the Use of Carfilzomib and Dexamethasone (Kd) By Lenalidomide-Refractory Status: An Interim Analysis from a Prospective Observational Study

Management of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Proteasome Inhibitor Based Therapy at First Relapse in Routine Clinical Practice in Germany

Email alerts

ASH Publications

American Society of Hematology

Subcutaneous Isatuximab Administration By an on-Body Delivery System (OBDS) in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Phase 1b Expansion Study Results

A Multi-Center, Phase 1b Study to Assess the Safety, Pharmacokinetics and Efficacy of Subcutaneous Isatuximab Plus Pomalidomide and Dexamethasone, in Patients with Relapsed/Refractory Multiple Myeloma

Real-World Evidence of the Use of Carfilzomib Among Multiple Myeloma Patients with at Least One Prior Therapy across 10 European Countries and Israel

Real-World Evidence of the Use of Approved Carfilzomib Regimens in Patients Previously Exposed or Refractory to Lenalidomide: Updated Results from a Prospective Observational Study

Patient's Preference for Making Informed Treatment Decisions Confidently: Results from a Large Multiple Myeloma Patient Survey across 12 Countries in Europe and Israel

Real-World Evidence of the Use of Carfilzomib and Dexamethasone (Kd) By Lenalidomide-Refractory Status: An Interim Analysis from a Prospective Observational Study

Management of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Proteasome Inhibitor Based Therapy at First Relapse in Routine Clinical Practice in Germany

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only